Filters

Renhua Wan

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
BMC Cancer|May 14, 2024
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinomaYongqiang Xiao, Wei Deng, Laihui Luo, et al.
Medicine|March 22, 2018
Situs inversus totalis with solid pseudopapillary pancreatic tumor: A case report and review of literatureDeng Xiang, Jiannan He, Zimeng Fan, et al.
Frontiers in Oncology|October 14, 2022
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experienceLaihui Luo, Yongqiang Xiao, Guoqing Zhu, et al.
BMC Cancer|April 25, 2025
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinomaWei Deng, Jin Xie, Tao Wang, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
BMC Cancer|May 14, 2024
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinomaYongqiang Xiao, Wei Deng, Laihui Luo, et al.
Medicine|March 22, 2018
Situs inversus totalis with solid pseudopapillary pancreatic tumor: A case report and review of literatureDeng Xiang, Jiannan He, Zimeng Fan, et al.
Frontiers in Oncology|October 14, 2022
Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experienceLaihui Luo, Yongqiang Xiao, Guoqing Zhu, et al.
BMC Cancer|April 25, 2025
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinomaWei Deng, Jin Xie, Tao Wang, et al.
Pageof 3
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us